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Genome-Wide ENU Mutagenesis Review
to Reveal Immune Regulators
nude, and the numerous transgenic and knockout strains
that are a modern workhorse.
Established sources for genetic variants in the mouse
Keats A. Nelms and Christopher C. Goodnow1
Australian Cancer Research Foundation
Genetics Laboratory
Medical Genome Centre nevertheless limit investigation to isolated patches of
the phenome. A limited range of alleles exists amongJohn Curtin School of Medical Research
Canberra ACT 2601 inbred and outbred mouse strains, since strongly delete-
rious alleles are rapidly selected against. Relatively fewAustralia
spontaneous mouse mutants exist for immunology, be-
cause it is hard to recognize an immunological mutant by
looking in a cage during the course of normal inbreeding.A complete list of molecular components for immune
Transgenic mice, especially where the transgene is tar-system function is now available with the completion
geted by homologous recombination, allow limitlessof the human and mouse genome sequences. How-
possibilities in terms of the genes and types of allelesever, identification and functional annotation of genes
that can be investigated, but they require a great deal ofinvolved in immunological processes require a discov-
background knowledge and investment in constructionery methodology that can efficiently and broadly ana-
and analysis which must be performed one gene at alyze the complex interplay of these components in
time. Large scale insertional knockout programs are ac-vivo. Our recent experience indicates that genome-
celerating the construction of mouse mutants (Zam-wide chemical mutagenesis in the mouse is an ex-
browicz et al., 1998), but because the approach stilltremely powerful methodology for the identification of
examines one gene at a time, these approaches alsogenes required for complex immunological processes.
limit the field to analyzing a small fraction of the genome
and superficial digging into the phenome. To illuminateMining the Phenome: Opportunity and Challenge
immune regulators, it is often necessary to perform com-The assembled sequences of the human and mouse
plex antigen challenges or crosses to susceptible strainsgenomes provide a remarkable opportunity in the form
or transgenic models, efforts that are prohibitive whenof a complete list of genes controlling the immune sys-
scaling up a “one gene at a time” approach.tem. Solutions to long standing immunological ques-
Genome-wide, random mutagenesis with the ethylat-tions such as the cause and treatment of autoimmunity,
ing chemical N-ethyl-N-nitrosourea (ENU) provides athe prevention of allergy and transplant rejection, and
way to produce and screen genetic variants for immuno-the enhancement of suitable immune responses to in-
logical functions in the mouse in a highly parallel manner,fection, parasitism, and cancer lie in using this list to
thousands of genes at a time, allowing much wider andidentify the molecular circuitry underpinning immune
deeper mining of the phenome. Here, we summarize ourcell responses. For example, the limitations of the cur-
recent experience and the current status of this strategy,rent gold standard immunosuppressive drugs cyclospo-
and discuss its strengths and limitations.rin and tacrolimus probably stem from their interference
with tolerogenic as well as immunogenic signaling in
lymphocytes (Glynne et al., 2000b). Revealing more ef- Overall Concept
The overall aim of ENU mutagenesis is to produce afective targets for long-term graft acceptance or treat-
ment of autoimmunity will depend upon resolving bio- high rate of point mutations genome wide, at random,
in the mouse germline (Figure 1). As a complement tochemical pathways that are exclusively immunogenic
from pathways that serve both immunogenic and tolero- gene knockout strategies, genome-wide mutagenesis
in mice requires no foreknowledge about the target se-genic responses to antigen.
With the genome sequence in hand as a surface map, quence or kind of mutation that should be induced.
Introducing point mutations has the advantage that ithow do we mine the “phenome,” the many layers of
molecular and cellular behavior that extend deep be- most often inactivates or alters the function of individual
protein domains rather than eliminating the protein alto-neath the sequence? How do we find and recognize key
regulatory and effector molecules? Sequence homology gether, making it harder for related proteins to compen-
sate, better mimicking the effects of drugs or naturaland patterns of mRNA or protein expression provide
valuable clues for where to start digging. Functional genetic variants, illuminating active sites in proteins,
and revealing specific functions of alternatively splicedstudies in cell culture, by overexpression, for example,
provide an early indication of function, but one that is forms. Breeding of the mutagenized stocks can be per-
formed such that libraries of mice are created whereoften incomplete or misleading. The in vivo phenotype
of genetic variants in humans and animals provides the potentially every gene product is mutated to inactivate
discrete domains in individual mice. The mutagenizedfirmest definition of function. In this regard, the mouse
is the Rosetta stone for immunology, by allowing the mouse libraries can then be screened for key immuno-
logical functions, to identify genetic variants in manycellular and biochemical roles of individual gene prod-
ucts to be clearly revealed through allelic variants such of the key regulatory components and provide animal
models so as to understand their role.as H-2 congenic strains, spontaneous mutants such as
The concept of genome-wide mutagenesis is well
proven in fruit flies and nematode worms. It was used1 E-mail: chris.goodnow@anu.edu.au
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Figure 1. Genome-Wide Random Mutagene-
sis Is a Powerful Approach to Identifying
Genes Involved in a Wide Range of Pheno-
types in Mice
(A) Comparison of gene knockout analysis of
gene function to genome-wide mutagenesis.
Gene knockouts result in the inactivation of
one gene at a time and a limited range of
phenotypes. Genome-wide ENU mutagene-
sis results in the simultaneous, random muta-
tion of many genes and can result in a wide
range of phenotypes due to the varied effect
of point mutations within a gene ranging from
complete inactivation to subtle alteration of
protein function.
(B) Performing ENU mutagenesis on a specific
sensitized strain whose genetic background
predisposes it to a specific phenotype can lead
to the identification of a set of modifier genes
that may not be detected when mutagenesis
is performed on a wild-type genetic back-
ground. Random mutations in such modifier
genes may lead to the alleviation or exacerba-
tion of the phenotype in the sensitized strain.
by T.H. Morgan to create the first genetic maps of Men- Identifying ENU Mouse Mutants in One Generation
The supermutagenic effect of ENU for mouse spermato-delian inheritance in Drosophila, and revealed many of
the key genes controlling early embryonic patterning gonial stem cells was discovered by Russell and col-
leagues at Oak Ridge Laboratories in Tennessee, usingand development (Nusslein-Volhard and Wischaus,
1980), to name but two examples. Tens of thousands an assay called the “specific locus test” that was devel-
oped in the post-World War II period to measure theof mutagenized gametes and hundreds of thousands of
progeny need to be produced and screened to survey heritable mutagenic effects of radiation (Russell et al.,
1979). This one-generation breeding assay is performedmost of the genes in invertebrates. What makes it possi-
ble to carry out comparable efforts in mice is the extraor- by treating normal male mice (generation 0; G0 mice)
with ENU by intraperitoneal injection, creating a highdinary mutagenic efficiency of ENU in mouse spermato-
gonial stem cells. ENU has been shown to create a new burden of point mutations in the spermatogonial stem
cells. After waiting 7 weeks for mature sperm to beloss-of-function allele in any given locus, typically once
in every 700 gametes (Hitotsumachi et al., 1985). This formed from the mutagenized spermatogonia, the G0
males are mated with untreated females from a testermeans that it is possible to survey the majority of genes
in the genome for immunological or other functions in strain. The tester strain females are homozygous for
seven recessive visible mutations affecting pigment anda library of 14,000 mice derived from 700 gametes. Be-
cause each mouse in such a library is potentially homo- ear size, and the treated G0 males start with wild-type
alleles at each of these loci. Consequently, most prog-zygous for a different set of perhaps 12 loss-of-function
mutations, the immunological function of tens of thou- eny (generation 1; G1) appear wild-type because they
inherit a wild-type copy of each gene from the G0 fathersands of genes can be tested in a highly parallel manner
rather than one gene at a time. Multiplex screening of and a defective copy from the mother. Each time a G1
mouse is conceived from a sperm carrying a new loss-genetic variants enables deeper exploration through in-
tensive immunological tests and incorporation of special of-function mutation in one of the seven specific loci,
the new mutation is immediately visible by a differencetransgenic models (discussed below).
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in color or ear size. By testing thousands of such G1 loss of one copy can register as a clear phenotype, pro-
progeny, Russell and colleagues showed that a new vided one assays in a sufficiently sensitive way. Strate-
loss-of-function mutation in a specific locus was pro- gies to tease these out with sensitized/enhancer screens
duced on average once in every 700 gametes using an are discussed further below.
optimized dose and treatment regime (Hitotsumachi et Loss-of-function mutations in tumor suppressor
al., 1985). Adaptations of this one-generation breeding genes represent a variation on haploinsufficiency. Inher-
strategy to other gene loci have established the general- itance of a single wild-type copy of a tumor suppressor
ity of this mutation rate, although some loci appear par- gene is often insufficient to prevent cells from losing the
ticularly easy to mutate to loss of function while others remaining copy and becoming neoplastic. A dominant
are more difficult (Bode, 1984; Cordes and Barsh, 1994; ENU mutation causing multiple intestinal adenomas,
Lewis et al., 1991; Shedlovsky et al., 1993). The predomi- Min, was originally detected in a one-generation screen
nant mutation is in an A:T base pair, either as a transition because of anemia secondary to bleeding colonic can-
or transversion; 64% of the mutations are missense, cer polyps (Moser et al., 1990). This strain carries a loss-
10% nonsense, and 26% cause errors in mRNA splicing of-function mutation in the mouse homolog of the human
(Justice et al., 1999). tumor suppressor gene APC, and has been a valuable
Similar one-generation breeding strategies have been preclinical model for developing drugs against human
used to discover new ENU-induced mutations at pre- colon cancer. In our own program, we have also identi-
viously unknown loci by breeding ENU-treated males fied two dominant mutations that represent loss of func-
with wild-type females rather than a tester strain. Since tion in tumor suppressor genes (P. Papathanasiou, A.
only the paternal genome is mutated in this case, only Loy, K.A.N., and C.C.G., unpublished data).
dominant mutations can be detected in the resulting G1 The one-generation breeding strategy has been used
animals. Dominant mutations are of three chief types: on a large scale recently in two extensive mouse muta-
gain-of-function, dominant interfering, and haploinsuffi- genesis programs conducted at Harwell in the United
ciency. Rare gain-of-function mutants can be extremely Kingdom (Nolan et al., 2000) and in Munich, Germany
informative, as in the Lurcher mutant strain where a (Hrabe de Angelis et al., 2000). These programs screened
point mutation in the 2 glutamate receptor results in tens of thousands of G1 animals for behavioral and
apoptosis of Purkinje cells and the characteristic gait of blood defects, yielding over 300 confirmed mutant
these mice (Zuo et al., 1997). Many dominant interfering mouse strains. Of these new mutant strains, 39 were
mutations causing cataracts have been induced by ENU identified to have mutations affecting the immune sys-
using a one-generation breeding strategy (Favor et al., tem with alterations in basal immunoglobulin levels (in-
1991). Most of these appear to reflect misfolded proteins cluding IgE) or altered expression of surface proteins
that interfere with normal lens structure (Klopp et al., on peripheral blood lymphocytes (Hrabe de Angelis et
1998). Misfolded proteins can be toxic to cells and cause al., 2000).
phenotypes that have little relevance to the normal func-
tion of the protein. A small fraction of genes are overtly Three-Generation Strategies to Detect Recessive
haploinsufficient, such that loss of function in a single Mutations Genome Wide
copy reduces activity so drastically that a role for the
The majority of functional gene defects induced by ENU
gene can be readily detected in the heterozygous state.
will be loss-of-function variants that behave as recessive
A number of the homeobox-containing developmental
traits, and will only be detectable after breeding to ho-regulators exhibit this characteristic, and this may partly
mozygosity or to an existing mutant. A shortcut to revealreflect monoallelic expression in individual cells. In the
new recessive mutations in two generations is by breed-immune system, monoallelic expression of the Pax5
ing individual G1 males with females carrying a chromo-transcription factor occurs in early B cell progenitors
somal deletion (Rinchik et al., 1990; Shedlovsky et al.,and in mature B cells (Nutt et al., 1999). When mutations
1988). Only the small fraction of the genome encom-occur in one Pax5 allele, the monoallelic expression
passed by the deletion can be screened for recessivepattern leads to haploinsufficiency and results in the
mutations in this way. To reveal recessive mutationsdeletion of B cells expressing the mutant allele.
on a genome-wide basis requires a three-generationENU-induced dominant visible mutations have been
pedigree structure (Figure 2). To screen a large fractionproduced in PAX6 (small eye, Neuherberg), the brachyury
of genes, hundreds of such pedigrees must be createdgene (Tkt1), and the c-kit tyrosine kinase (white spotting).
in parallel.In the latter two examples, the dominant defects are
A three-generation pedigree structure which we haveonly detected at the very end of the neural tube or at
used successfully to reveal many new immunological mu-the extremities of melanocyte migration, where the dos-
tants is shown schematically in Figure 2. In each pedi-age of the normal gene product appears to be at its
gree, all of the mutagenized chromosomes that segre-most limiting. Thus, the ability to detect the loss of one
gate among the offspring come from a single foundercopy of these genes may primarily reflect fortuitous use
G1 male, who can be estimated to carry 100 loss-of-of a highly sensitive assay. A sensitive assay for diurnal
function mutations. Each G1 male is mated to a wild-rhythm involving activity measurements repeated over
type female, and then to his G2 daughters. The resulting30 days was used to identify a single dominant mutation,
G3 offspring have a 1/8 chance of being homozygousClock, among over a thousand G1 animals tested (Vita-
for any individual mutation carried by the founding G1terna et al., 1994). In reality, many gene products are lim-
male. If four G3 offspring from four G2 mothers areiting in signaling pathways in development (Simon et al.,
screened in each pedigree (16 G3 mice in total), it can1991) and in the immune system (Cornall et al., 1998;
Cyster et al., 1996; Rathmell et al., 1996), such that the be shown that at least one G3 animal would be expected
Immunity
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Figure 2. Breeding of ENU-Treated Mice to Reveal Recessive Mutations on Wild-Type Genetic Background
G1 mice carrying approximately 100 independent loss-of-function mutations become the founders of independent pedigrees by outcrossing
G1 males to wild-type females (1) or intercrossing unrelated mutagenized G1 mice (2). Recessive mutations become homozygous in G3 mice,
and these mice are screened for specific immunological phenotypes.
to be homozygous for 78 of the estimated 100 founding cesses relevant to human health. Second, the burden
of mutations could mean that most phenotypic abnor-mutations in the pedigree. Assuming the G1 male carries
100 loss-of-function mutations, the G3 mice will be ho- malities observed represent complex interactions be-
tween multiple mutations that might prove difficult tomozygous for a mode of 12 different loss-of-function
mutations, providing a highly parallel method to survey resolve or fail to breed true. Third, it is logistically difficult
to track hundreds of three-generation pedigrees and togene function genome wide.
An alternative three-generation breeding strategy that screen the animals for nonvisible traits such as immuno-
logical abnormalities. Fourth, the application of ENUwe now prefer initiates each pedigree with a G1 male
paired to an unrelated G1 female (Figure 2). Each of mutagenesis to immunologically well-characterized in-
bred strains such as C57BL/6 to facilitate detection andthese founding G1 grandparents contributes100 loss-
of-function mutations, and the total pool of 200 muta- analysis of immune system mutants has not been exten-
sively examined.tions are brought to homozygosity by intercrossing their
G2 progeny as brother-sister pairs. If four G3 progeny Genome-wide three-generation screens for recessive
mutations affecting embryonic and neonatal mice haveare tested from each of four G2 pairs (16 G3 mice in
total), it can be shown that 100 of the 200 founding been successfully performed using the strategy above
by several groups, attesting to the general feasibility ofmutations will be represented by at least one homozy-
gous animal. This two-founder strategy has four advan- this approach. Bode and colleagues (Bode et al., 1988)
mutagenized (C57BL/6xCBA) F1 animals to produce ap-tages over the daughter-father strategy: (1) it surveys a
larger number of mutations per G3 animal; (2) it screens proximately 25 G3 progeny in each of 105 daughter-
father pedigrees. The G3 mice were screened to dis-mutations on the X chromosome; (3) it is logistically
more straightforward because no rotation of breeders cover mouse models of the human metabolic disorder
phenylketonuria at 1 week of age while the G3 pupsis needed; and (4) the breeders are younger, and a higher
proportion of unaffected G3 siblings are carriers to help were still caged with their G2 mothers. Screening at
this age minimizes the number of cages and trackingpropagate a recessive mutation of interest.
While three-generation strategies conceptually pro- logistics enormously. Blood levels of phenylalanine were
tested using the standard Guthrie test performed onvide a highly parallel method to survey most of the genes
in the genome for immunological functions, doubts human neonates, and one pedigree with several G3 ani-
mals affected by hyperphenylalaninemia was identi-about their feasibility have centered on four key issues.
First, the large number of homozygous loss-of-function fied. Propagation and mapping of the mutation led to
its identification in phenylalanine hydroxylase, providingmutations in each G3 animal may prevent animals from
surviving to maturity because of the burden of lethal a valuable model for the corresponding human disease.
Harding et al. (1992) produced 135 pedigrees of ENU-mutations. Mature animals are essential to screen for
immunological disorders, cancer, and many other pro- mutagenized BTBR strain mice containing 10–15 G3 off-
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spring in each, and screened weaned mice for amino ods (Townsend et al., 2001). The presence of multiple
acid metabolism defects by placing them on a high pro- affected siblings in a pedigree provides another repeat
tein diet for 3 days and analyzing urine spots from the measure that greatly increases specificity to differenti-
whole cage by ultraviolet illumination. They identified ate true mutants from chance animals, and this is a
one recessive mutant with sarcosinemia, providing an major advantage of recessive traits. Likewise, the ability
animal model for this human genetic disorder. Anderson to propagate from healthy sibling carriers is an addi-
and colleagues (Kasarskis et al., 1998) mutagenized tional advantage of recessive traits, compared to domi-
C57BL/6 mice and established 130 three-generation nant traits which are very difficult to propagate if animals
daughter-father pedigrees. The daughters were sacri- are infertile or if identifying carrier individuals precludes
ficed at 10.5 days of gestation to screen for recessive breeding.
mutations disrupting neural tube closure and morphol-
ogy in the embryos. Four recessive mutant strains were Mapping and Identifying ENU-Induced Mutations
identified that mapped to single genes on chromosomes Two parallel paths of biological and genetic analyses
1, 6, 12, and 16. can be pursued to pinpoint the cellular and molecular
To establish the feasibility of this strategy for revealing defect in each new immunological mutant generated
genes regulating the immune system and cancer in ma- (Figure 3A). Because each new strain is isogenic on
ture inbred mice, we mutagenized C57BL/6 mice and the C57BL/6 strain background from the outset, this
established 185 daughter-father three-generation pedi- facilitates detailed immunohistochemistry, flow cytome-
grees (K.A.N., A. Loy, P. Papathanasiou, L. Miosge, L. try, cell transfer, mixing experiments, and constructing
Wilson, S. Chaudhry, and C.C.G., unpublished data). At bone marrow radiation chimeras reconstituted with a
least 25 G3 offspring in each pedigree were aged to 6–9 mixture of mutant C57BL/6 and wild-type C57BL/6-Ly5a
months in order to detect mature onset disorders. Blood congenic bone marrow. For most of the immunological
from the mice was screened for B and T cell subsets mutants we have isolated, these approaches have re-
by flow cytometry, yielding over 20 different strains with solved the cell lineage and differentiation stage express-
recessive disorders ranging from absence of T cells or ing the primary defect and often suggested the biochem-
T cell subsets and deficiencies of T and/or B cells to ical process that is disrupted. Once the primary cell
hyperactivity of T cells and hypergammaglobulinemia. type and differentiation stage is known, a molecular
Four strains with spontaneous cancer predisposition fingerprint of changes in gene expression caused by the
were established, one with a dominant T cell leukemia, mutation can be obtained by profiling mRNA on DNA
one with a range of tumors (primarily B or T lymphomas microarrays. We have previously established the ability
or osteosarcoma), one with primitive hemopoietic cell of microarrays to identify selective defects in lympho-
tumors, and one with hepatocellular carcinoma. In paral- cyte signaling pathways and link these to downstream
lel, a large number of strains were established with re- targets (Glynne et al., 2000a), and emphasized the need
cessive defects affecting many other body systems, no- to perform at least two replicates (Glynne et al., 2000c)
tably the nervous system, obesity, skin and hair, skin and the importance of starting with highly purified FACS-
mast cells, mucosal goblet cells, skeleton, and kidney.
sorted cells that are as closely matched between test
Almost all of the mutations breed true as simple Mende-
and control groups (Glynne et al., 2000b). Amplification
lian traits, and over half of the mutations appear to be
of mRNA by in vitro transcription enables clear mRNA
novel, in that the chromosomal location and the pheno-
profiles to be readily measured from one or two milliontype do not correspond to any known mutant or knock-
sorted resting lymphocytes (Glynne et al., 2000b).out mouse strain.
In parallel to obtaining a precise cellular and molecularSeveral key points are underscored by our experience
phenotype for each mutant, a generic mapping ap-with genome-wide screening for recessive immunologi-
proach enables rapid localization of each mutation to acal defects. Foremost is the sensitivity and specificity
particular chromosomal region. In this approach, theof different thresholds and parameters for recognizing
mutation is mapped by cosegregation of the mutationputative mutants. Because rare mutant animals of inter-
with genetic markers interspersed throughout the ge-est must be readily detected against a background of
nome. The initial step of this approach requires thathundreds of phenotypically normal individuals, it is im-
mutants on the C57BL/6 background be outcrossedportant to use quantitative screening parameters that
with a second inbred mapping strain resulting in F1do not have too great a coefficient of variation in the
progeny that acquire one set of chromosomes from theparental strain. Multiparameter flow cytometry is ideally
C57BL/6 strain and the other set from the mapping strainsuited to this task. Because of the need to minimize
(Figure 3A). Following the initial outcross, recessive mu-other sources of variability, it is far preferable to muta-
tations are mapped most efficiently by intercrossing F1genize and screen a well-characterized inbred strain like
carrier mice in brother-sister pairings that yield F2 prog-C57BL/6 and to ensure pathogen-free status. Ideally, a
eny of which 25% are homozygous for the recessivethreshold should be set for a screened trait such that
mutation (Figure 3A). The mapping efficiency of such F1less than 1% of normal animals would exceed the
intercrosses is high, because every meiosis is informa-threshold. Specificity of the screen is greatly improved
tive (i.e., crossing over can occur between every pair ofby repeat testing, hence a blood screen that can be
F1 chromosomes) and the fertility and fecundity of F1repeated on apparently abnormal individuals is far better
mice is very high. An alternative to the intercross is thethan a one-off assay such as a terminal test. Similarly,
backcross strategy that is required when the mappedthe accuracy of detecting rare events is enhanced signif-
mutation is dominant or when a recessive mutation isicantly by redundant screens where a specific parameter
is assayed by independent detection reagents or meth- suppressed by the genetic background of the mapping
Immunity
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Figure 3. Gene Identification in Genome-Wide Mutagenesis
(A) Parallel biological and genetic analyses in novel strains of mutant mice lead to the identification of candidate genes whose mutation results
in the phenotypes observed in the mice.
(B) Intercross breeding strategy for the mapping of recessive mutations by genetic linkage analysis. Mutant mice (B6) are outcrossed to a
mapping strain (NOD) to produce F1 hybrid carrier mice that are then intercrossed to produce F2 progeny, 25% of which will be homozygous
for the recessive mutation. DNA from F2 mutant mice is pooled and analyzed by microsatellite markers. B6 and NOD alleles are distinguished
by the size of PCR fragments in gel electrophoresis. Markers closely linked to the mutation will yield only the B6 allelic fragment in F2 mutant




strain. In either the intercross or backcross strategy, two Obtaining an accurate map location for the mutated
gene is the key step prior to initiating studies to establishgenerations and 4–6 months are required, depending on
the age that the mutant phenotype can be detected. the identity of the mutated gene. On average, 60–100
genes must be considered as candidates for the mu-Meiotic recombination in F1 mice acts as a genetic
shuffle that can be used to distinguish regions of the tated gene when mutations are mapped to an interval
of 1–2 cM corresponding to approximately 2–4 Mb of thegenome that are closely linked to the mutation from
regions that are unlinked. These regions are determined genome. The ensuing process of identifying the mutated
gene is less defined in comparison to the genetic map-by linkage analysis in the last step of the mapping pro-
cess by analyzing the recombinant chromosomes inher- ping of the mutation, and can be greatly influenced by
the results of biological analyses obtained on the mutantited by F2 mice with a panel of genetic markers that
span the genome (Figure 3B). In the case of recessive strain. This is particularly true when aspects of the mu-
tant phenotype have been observed in previously de-intercrosses, this is done by analysis of genomic DNA
from F2 mice that exhibit the mutant phenotype and scribed knockout or spontaneous mutant mice. In such
cases, resequencing of one candidate gene often re-are thus homozygous for the mutation. Analysis of only
mutant F2 mice ensures that the mutated gene and the veals the novel mutation. In other cases, no knockout
or mutant strains exist that suggest a candidate genegenomic regions closely linked to it are homozygous for
the C57BL/6 allele. In contrast, genomic regions that in the mapped interval. In our experience, a majority of
ENU-induced recessive mutations fall into this categoryare unlinked and therefore inherited randomly will exhibit
the 1:1 ratio of C57BL/6 and mapping strain alleles also and the identification of the mutated gene in these novel
mutants requires a multifaceted approach.observed in the F1 parents. Thus, analyses of pooled
genomic DNA from mutant F2 mice with closely linked After obtaining a chromosomal map location, ad-
dressing several key questions can aid in the identifica-genetic markers will only yield the C57BL/6 allele,
whereas analyses with unlinked markers will yield an tion of uncharacterized genes containing ENU-induced
mutations. The first and most important question is:equal mix of C57BL/6 and mapping strain alleles (Figure
3B). Using the pool of 25 mutant mice derived from a what are the genes that exist in the mapped interval?
Genomic sequence databases and the annotation oftotal of 100 F2 intercross mice, linkage can be detected
at a 95% confidence level between the mutation and these databases are the critical tools used to address
this question. If the genomic sequence data is complete,genetic markers spaced at 28 cM intervals across the
genome (Silver, 1995). This coverage is accomplished sequencing and expression analysis strategies may be
readily implemented to identify the mutated gene. Avery efficiently with a panel of 60 independent genetic
markers run on one F1 DNA control and one pooled second key question addressed by the biological analy-
sis of each mutant is whether a specific cell type orDNA sample per marker.
Once a preliminary chromosomal map location is de- tissue is intrinsically affected in the mutant mice. In the
case of immunological mutants, this may often be ad-termined, the genetic location of the mutation is more
accurately defined by fine mapping analyses. Such anal- dressed using bone marrow chimeras as discussed
above. When a specific cell or tissue is affected, identi-yses require that individual mutant mice be analyzed
with genetic markers in a defined chromosomal region. fying candidates is greatly facilitated by delineating the
genes in the interval that are expressed specifically inUltimately, the location of each mutation is delimited
by specific genetic markers that flank the site of the the affected cells or tissue. Such data can be rapidly
obtained using expression array assembled with genemutation and detect recombinant chromosomes in indi-
vidual mutant F2 mice. Additional markers very close to sequences from the mapped interval. This expression
data may also be used to determine whether the inducedthe mutation will only very rarely have points of recombi-
nation between the marker and the mutation. This ap- mutation occurs in a cis-acting element or RNA stability
sequence that is required for expression in the affectedproach of pooling and performing linkage analysis on
25 F2 intercross mutant mice is predicted to lead to cell or tissue. In contrast, mutations in splice sites are
readily detected even from limited numbers of targeta 1–2 cM map position for a mutation. Indeed, we have
achieved this accuracy with many mutants. However, cells using RT-PCR and resequencing of candidate
genes while coding sequence mutations are detectedin some cases, the limited availability of usable genetic
markers between C57BL/6 and our current mapping by cDNA or exon resequencing.
Although identification of the genetic lesion in novelstrain, NOD, have limited the mapped interval to 5–15
cM. Currently, simple sequence length polymorphism mutant mice is a potential “bottleneck” in the gene dis-
covery process, this bottleneck can be readily ad-(SSLP) or “microsatellite” markers are the primary tool
used for such genome-wide mapping and fine mapping dressed with existing technology. In particular, high-
throughput resequencing of all the cDNAs or exons inanalyses. At present, such markers can be restricted in
their genomic density and utility between specific the mapped interval is the most straightforward option
and could potentially be used to identify all mutationsmouse strains. Thus, obtaining an accurate map position
to less than 1–2 cM can be marker limited. With the in a relatively large mapped interval. Such efforts can
be streamlined significantly by further delimiting thecompilation of genomic sequence information from mul-
tiple strains of mice, it is anticipated that a very high- mapped interval with fine mapping. However, from a
practical standpoint, large scale resequencing effortsdensity microsatellite and single-nucleotide polymor-
phism (SNP) marker panel will be readily assembled. may be cost prohibitive. Thus, emerging technologies
focused on the rapid and economical identification ofSuch a panel of high-density genetic markers would
greatly enhance the accuracy and efficiency of mutation point mutations may play a key role in mutation detec-
tion in the near future.mapping procedures.
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Mining Deeper into the Phenome Phenotypes that Require Time and/or Multiple Steps
Genes contributing to spontaneous disorders such asA key issue that remains to be fully explored is how
lymphoid cancer or autoimmune diabetes may normallydeeply we will be able to mine the phenome using Men-
be hidden by the need for multiple genetic abnormalitiesdelian mutations in individual genes in mice, whether
to be present before the defect becomes penetrant asthese be induced by targeted transgenesis, insertion
a clinical phenotype, and an inordinate amount of time.trap, or with ENU. Only a subset of genes and mutations
One solution to this problem is to screen for surrogatehas a sufficiently extreme phenotype that they will be
phenotypes, as discussed above, but in many casesreadily recognized by a broad, superficial survey of
these will not exist. Another strategy is to test for thesephysiological systems. For example, the mouse small
genes on a strain background where some of the stepseye mutation was readily detected by its externally visi-
have been taken to start with; for example, a p53 knock-ble effect on eye development, but it was only decades
out strain that is already one step toward cancer, alater that striking abnormalities in pancreatic islet cell
TCR transgenic strain that already has a high level ofdevelopment were fortuitously revealed by specific im-
subclinical autoimmune insulitis, or a drug treatmentmunohistochemical staining (Sander et al., 1997; St-
that mimics one of the steps.Onge et al., 1997). The majority of illuminating mutations
Lethal Mutationswill likely be buried for one of several reasons outlined
Perhaps 10% of mammalian genes serve essential func-below, requiring special efforts to unearth them. The
tions during fetal life, such that homozygous mutantability to screen hundreds of mutations at a time by
mice will not survive to an age that an important immuno-ENU mutagenesis, and to do this on a transgenically
logical function could be revealed. Targeted construc-sensitized background, makes it feasible to apply these
tion of conditional knockout alleles provides a powerfulextra efforts on a genome-wide scale.
strategy to pursue immunological functions of essentialSurrogate Phenotypes
genes on a small scale. One solution to this problemMutations in genes critical to specific immunological
that has been used in Drosophila is to combine randomprocesses will frequently not be immediately apparent
ENU mutagenesis with an engineered chromosome thatby a spontaneous clinical disorder or a straightforward
allows mutations to be made homozygous in subsetsimmunological screen, and may in fact affect rare cell
of somatic cells by recombinase-mediated exchangetypes or processes that are not obvious without specific
between chromosome homologs (Golic and Lindquist,histological or biochemical analysis. The example of
1989; Theodosiou and Xu, 1998). Given the spectacularsubclinical defects in pancreatic islet cell development
advances in chromosome engineering that have beenin small eye mutant mice was mentioned above (Sander
achieved (reviewed in Mills and Bradley, 2001), it is con-et al., 1997; St-Onge et al., 1997). Identification of such
ceivable that the same strategy could be applied to screenphenotypes will require specialized knowledge and
for immunological genes chromosome by chromosomehighly focused assays such as high-throughput immu-
in mice.nohistological tests. Genes that alter such surrogate
Sensitized enhancer/suppressor screens provide an-traits are much more likely to be revealed if the histologi-
other solution to revealing later roles for genes that servecal screen can examine mutations in hundreds of genes
essential embryonic functions, borrowing another leafat a time rather than one gene at a time. Similarly, muta-
from the Drosophila geneticists’ textbook. An eleganttions that alter antigen-specific selection and responses
example of this strategy was used to reveal the interme-will often be hidden by the variability and diversity of
diate genes between the sevenless receptor tyrosineclones in a polyclonal repertoire of T and B cells. Many
kinase and its nuclear targets in Drosophila eye develop-such defects will be made visible by performing ENU
ment (Simon et al., 1991). The intermediate genes in-mutagenesis on the background of an antigen-specific
clude essential embryonic proteins such as Grb-2, Sos,TCR or Ig receptor transgenic strain (Figure 1B).
and Ras, which were never revealed in recessive screensPhenotypes that Require a Challenge Test
genome wide because of lethality. By partially crippling
An important class of immunological genes and muta-
the receptor kinase, correct eye development became
tions that require in depth screening procedures are sensitive to the loss of a single copy of the intermediate
those affecting the dynamics and type of response to genes in heterozygous mutant animals (allowing the mu-
immunological challenge. Included in this class would tant genes to be found), while the remaining wild-type
be gene mutations that suppress inflammatory, allergic, copy of these genes remained sufficient to support em-
or autoimmune responses. A key issue in the identifica- bryonic development. Evidence that similar strategies
tion of such mutations is the normal variability of immune could be employed in mice comes from the ability to
responses even to highly purified antigens in an inbred reveal heterozygous loss-of-function deficits in numer-
strain. Even a false positive rate of 5% can lead to an ous lymphocyte signaling molecules when placed onto
unacceptable level of misdirected effort. Thus, identi- a homogeneous lymphocyte repertoire of an Ig or TCR
fying mutants that affect the response to immunological transgenic mouse (Cornall et al., 1998; Cyster et al.,
challenge on the background of an ENU-mutagenized 1996; Rathmell et al., 1995). The key issue for the suc-
strain will require highly reproducible immunization pro- cess of these approaches is the challenge of detecting
tocols. Again, such variability problems may be ad- a relatively subtle change in one mouse against a back-
dressed by screening for ENU-induced mutations in ground of normal variability. The specificity of the en-
mice that are genetically hardwired with a TCR or Ig hancer of the sevenless screen benefits from measuring
transgene or a mutation, to give a more stereotypic hundreds of replicate developmental events in the many
response. The logistical issue of mouse fertility must be ommatidia of each individual fly. The detection of het-
erozygous lymphocyte defects depends similarly onsolved if the genetically challenged mice cannot breed.
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repetition increases the mutagenic effectiveness of N-ethyl-N-nitro-comparing the distribution of surface Ig densities on
sourea in mouse spermatogonia. Proc. Natl. Acad. Sci. USA 82,many lymphocytes in individual mice.
6619–6621.
Hrabe de Angelis, M.H., Flaswinkel, H., Fuchs, H., Rathkolb, B.,Future Directions
Soewarto, D., Marschall, S., Heffner, S., Pargent, W., Wuensch, K.,
The rapid expansion and increased accessibility of ge- Jung, M., et al. (2000). Genome-wide, large-scale production of mu-
nomic technologies and information has resulted in the tant mice by ENU mutagenesis. Nat. Genet. 25, 444–447.
successful application of genome-wide ENU mutagene- Justice, M.J., Noveroske, J.K., Weber, J.S., Zheng, B., and Bradley,
sis in the mouse for the discovery of genes in a wide A. (1999). Mouse ENU mutagenesis. Hum. Mol. Genet. 8, 1955–1963.
variety of immunological, physiological, and develop- Kasarskis, A., Manova, K., and Anderson, K.V. (1998). A phenotype-
mental processes. These successes will undoubtedly based screen for embryonic lethal mutations in the mouse. Proc.
Natl. Acad. Sci. USA 95, 7485–7490.lead to the increased use and inevitable refinements of
Klopp, N., Favor, J., Loster, J., Lutz, R.B., Neuhauser-Klaus, A.,the current methodology. Complete assembly and full
Prescott, A., Pretsch, W., Quinlan, R.A., Sandilands, A., Vrensen,annotation of the human and mouse genomic sequence
G.F., and Graw, J. (1998). Three murine cataract mutants (Cat2) aredatabases as well as the availability of sequences from
defective in different -crystallin genes. Genomics 52, 152–158.
different mouse strains will likely have the greatest im-
Lewis, S.E., Barnett, L.B., Sadler, B.M., and Shelby, M.D. (1991).pact on gene discovery in the near term. In addition,
ENU mutagenesis in the mouse electrophoretic specific-locus test,
application of the sequencing technologies and capabil- 1. Dose-response relationship of electrophoretically-detected muta-
ities resulting from genome sequencing efforts will have tions arising from mouse spermatogonia treated with ethylnitro-
sourea. Mutat. Res. 249, 311–315.a great impact on the rate of mutation identification in
novel mutant mouse strains. The advent of new technol- Mills, A.A., and Bradley, A. (2001). From mouse to man: generating
megabase chromosome rearrangements. Trends Genet. 17,ogies such as high-throughput SNP mapping will also
331–339.greatly expedite gene discovery. Ultimately, the fusion
Moser, A.R., Pitot, H.C., and Dove, W.F. (1990). A dominant mutationof all of these technologies will facilitate the understand-
that predisposes to multiple intestinal neoplasia in the mouse. Sci-ing of many of the most complex questions currently
ence 247, 322–324.facing immunologists.
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